Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Impaired fibrinolysis may be associated with development of atherothrombotic cardiovascular disease (CVD) in metabolic syndrome or type 2 diabetes. Plasma plasminogen activator inhibitor (PAI)-1, a potent inhibitor of fibrinolysis, is elevated in a number of clinical situations that are associated with high incidence of CVD. Impaired fibrinolysis resulting from high plasma PAI-1 can lead to excessive fibrin accumulation within vessels, resulting in atherothrombosis. Increased expression of PAI-1 is found in atherosclerotic lesions in humans, especially atherosclerotic plaques in patients with type 2 diabetes. This increased vascular expression of PAI-1 promotes neointima formation via accumulation of fibrin or fibrinogen as a result of inhibited clearance of platelet-fibrin thrombi. PAI-1, an acute phase protein, also could be involved in vascular inflammation. PAI-1 may be associated not only systemically but also locally with development of CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Prevalence and trends in obesity among US adults, 1999–2000
Flegal, K. M. (2002) · JAMA · doi:10.1001/jama.288.14.1723 · Cited by 6,190
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Diabetes and Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.1979.03290450033020 · Cited by 2,936
Yusuf, S., Hawken, S., Ôunpuu, S., Bautista, L., Franzosi, M. G., Commerford, P., Lang, C. C., Rumboldt, Z., Onen, C. L., Lisheng, L., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67663-5 · Cited by 2,903
Pathophysiology of coronary artery disease
Libby, P., & Theroux, P. (2005) · Circulation · doi:10.1161/circulationaha.105.537878 · Cited by 1,965
Lifetime risk for diabetes mellitus in the United States
Narayan, K. M. V. (2003) · JAMA · doi:10.1001/jama.290.14.1884 · Cited by 1,515 · cited 1×
“CVD is the major cause of death in patients with type 2 diabetes in Western societies (7).”
BackgroundSattar, N., Gaw, A., Scherbakova, O., Ford, I., O’Reilly, D. S. J., Haffner, S. M., Isles, C., Macfarlane, P. W., Packard, C. J., Cobbe, S. M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000080897.52664.94 · Cited by 1,506
Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study
Kannel, W. B., & McGee, D. L. (1979) · Diabetes Care · doi:10.2337/diacare.2.2.120 · Cited by 1,203 · cited 3×
“Several epidemiologic studies have shown a 2- to 4fold increase in risk of CVD among patients with type 2 diabetes compared to subjects without diabetes (5, 6, 8).”
BackgroundFesta, A., D’Agostino, R., Tracy, R. P., & Haffner, S. M. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1131 · Cited by 1,057
Diabetes and obesity: the twin epidemics
Smyth, S., & Heron, A. (2006) · Nature Medicine · doi:10.1038/nm0106-75 · Cited by 643
Thögersen, A. M., Jansson, J.-H., Boman, K., Nilsson, T. K., Weinehall, L., Huhtasaari, F., & Hallmans, G. (1998) · Circulation · doi:10.1161/01.cir.98.21.2241 · Cited by 602 · cited 1×
“Elevated plasma PAI-1 may play a role in development of atherothrombosis in obese patients with type 2 diabetes, independently of other known cardiovascular risk factors (58).”
BackgroundEhrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4069 · Cited by 461
Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk
Juhan-Vague, I., Alessi, M.-C., Mavri, A., & Morange, P. E. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00279.x · Cited by 371 · cited 1×
“Plasma PAI-1 also is strongly correlated in subjects with metabolic syndrome and type 2 diabetes with metabolic syndrome components such as BMI, visceral fat, blood pressure, plasma insulin, triglyceride, free fatty acids, and HDL cholesterol (54-56).”
BackgroundChen, Y.-Q., Su, M., Walia, R. R., Hao, Q., Covington, J. W., & Vaughan, D. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.14.8225 · Cited by 217 · cited 2×
“The 5’-flanking region (promoter) of the human PAI-1 gene contains the transcription initiation site, a TATA box, and a regulatory sequence that confer transcriptional responsiveness to a number of mediators, including a glucocorticoid response element (59) that can mediate aldosterone responsiveness, a VLDL response…”
BackgroundEriksson, P., Nilsson, L., Karpe, F., & Hamsten, A. (1998) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.18.1.20 · Cited by 187 · cited 1×
“The 5’-flanking region (promoter) of the human PAI-1 gene contains the transcription initiation site, a TATA box, and a regulatory sequence that confer transcriptional responsiveness to a number of mediators, including a glucocorticoid response element (59) that can mediate aldosterone responsiveness, a VLDL response…”
BackgroundPandolfi, A., Giaccari, A., Cilli, C., Alberta, M. M., Morviducci, L., De Filippis, E. A., Buongiorno, A., Pellegrini, G., Capani, G., & Consoli, A. (2001) · Acta Diabetologica · doi:10.1007/s005920170016 · Cited by 144
Brown, N. J., Agirbasli, M., & Vaughan, D. E. (1999) · Hypertension · doi:10.1161/01.hyp.34.2.285 · Cited by 124 · cited 1×
“Short-term interruption of the renin-angiotensin-aldosterone system by either ACE inhibition or ARB decreases PAI-1 antigen, but the duration of this effect is greater for ACE inhibition than for Ang II receptor (AT1) receptor antagonism (95).”
Background
Cited by
Platelets, inflammation and tissue regeneration
Nurden, A. (2011) · Thrombosis and Haemostasis · doi:10.1160/ths10-11-0720 · Cited by 791
Adipose Tissue: The New Endocrine Organ? A Review Article
Wozniak, S. E., Gee, L. L., Wachtel, M. S., & Frezza, E. E. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0585-3 · Cited by 588
Cesari, M., Pahor, M., & Incalzi, R. A. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00171.x · Cited by 448
Role of the renin–angiotensin system in vascular inflammation
Marchesi, C., Paradis, P., & Schiffrin, E. L. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.05.003 · Cited by 432
Gualillo, O., González-Juanatey, J. R., & Lago, F. (2007) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2007.09.005 · Cited by 193
Metadata
- Authors
- Aso, Y.
- Venue
- Frontiers in Bioscience
- Publisher
- IMR Press
- Published
- 2007
- Volume
- 12
- Issue
- 8-12
- Pages
- 2957
- ISSN
- 1093-4715 (ISSN-L)
- 1093-9946
- DOI
- 10.2741/2285
- OpenAlex
- W2052417297
- Cited by
- 147
- References
- 19
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.